SEC Form 4 · accession 0001237899-17-000021
REGENERON PHARMACEUTICALS, INC. · REGN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Robert E Landry
Officer — SVP Finance & CFO
Period of report
Sep 1, 2017
Accepted (ET)
Sep 6, 2017 · 5:06 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000872589
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Sep 1, 2017 | M | 3,000 | $272.70 | A | 10,099 | D | |
| Common Stock | Sep 1, 2017 | F | 1,631 | $501.29 | D | 8,468 | D | |
| Common Stock | Sep 1, 2017 | F | 706 | $501.29 | D | 7,762 | D | |
| Common Stock | Sep 5, 2017 | S | 100 | $500.33 | D | 7,662 | D | |
| Common Stock | Sep 5, 2017 | S | 89 | $501.88 | D | 7,573 | D | |
| Common Stock | Sep 6, 2017 | S | 100 | $496.51 | D | 7,473 | D | |
| Common Stock | Sep 6, 2017 | S | 74 | $496.52 | D | 7,399 | D | |
| Common Stock | Sep 6, 2017 | S | 100 | $496.86 | D | 7,299 | D | |
| Common Stock | Sep 6, 2017 | S | 100 | $498.25 | D | 7,199 | D | |
| Common Stock | Sep 6, 2017 | S | 100 | $499.69 | D | 7,099 | D | |
| Common Stock | holding | — | — | — | 83 | I | By 401(k) Plan |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Non-Qualified Stock Option (right to buy)F2 | $272.70 | Sep 1, 2017 | M | 3,000 | D | — | Sep 9, 2023 | Common Stock | 3,000 | 57,000 | D |
Explanation of responses
- F1Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c).
- F2The stock option award vests in four equal annual installments, commencing one year after the date of grant.